Your browser doesn't support javascript.
loading
The concordance between nonclinical and phase I clinical cardiovascular assessment from a cross-company data sharing initiative.
Ewart, Lorna; Aylott, Mike; Deurinck, Mark; Engwall, Mike; Gallacher, David J; Geys, Helena; Jarvis, Philip; Ju, Haisong; Leishman, Derek; Leong, Louise; McMahon, Nick; Mead, Andy; Milliken, Phil; Suter, Willi; Teisman, Ard; Van Ammel, Karel; Vargas, Hugo M; Wallis, Rob; Valentin, Jean-Pierre.
Affiliation
  • Ewart L; *AstraZeneca R&D Mölndal, Pepparedsleden 1, 431 83, Mölndal, Sweden, GlaxoSmithKline, Park Road, Ware, Hertfordshire, SG12 ODP, UK, Novartis Pharma AG, PO Box, CH-4002, Basel, Switzerland, Amgen, Inc, One Amgen Center Drive, Thousand Oaks, CA 91320, Janssen Research & Development, a division
  • Aylott M; *AstraZeneca R&D Mölndal, Pepparedsleden 1, 431 83, Mölndal, Sweden, GlaxoSmithKline, Park Road, Ware, Hertfordshire, SG12 ODP, UK, Novartis Pharma AG, PO Box, CH-4002, Basel, Switzerland, Amgen, Inc, One Amgen Center Drive, Thousand Oaks, CA 91320, Janssen Research & Development, a division
  • Deurinck M; *AstraZeneca R&D Mölndal, Pepparedsleden 1, 431 83, Mölndal, Sweden, GlaxoSmithKline, Park Road, Ware, Hertfordshire, SG12 ODP, UK, Novartis Pharma AG, PO Box, CH-4002, Basel, Switzerland, Amgen, Inc, One Amgen Center Drive, Thousand Oaks, CA 91320, Janssen Research & Development, a division
  • Engwall M; *AstraZeneca R&D Mölndal, Pepparedsleden 1, 431 83, Mölndal, Sweden, GlaxoSmithKline, Park Road, Ware, Hertfordshire, SG12 ODP, UK, Novartis Pharma AG, PO Box, CH-4002, Basel, Switzerland, Amgen, Inc, One Amgen Center Drive, Thousand Oaks, CA 91320, Janssen Research & Development, a division
  • Gallacher DJ; *AstraZeneca R&D Mölndal, Pepparedsleden 1, 431 83, Mölndal, Sweden, GlaxoSmithKline, Park Road, Ware, Hertfordshire, SG12 ODP, UK, Novartis Pharma AG, PO Box, CH-4002, Basel, Switzerland, Amgen, Inc, One Amgen Center Drive, Thousand Oaks, CA 91320, Janssen Research & Development, a division
  • Geys H; *AstraZeneca R&D Mölndal, Pepparedsleden 1, 431 83, Mölndal, Sweden, GlaxoSmithKline, Park Road, Ware, Hertfordshire, SG12 ODP, UK, Novartis Pharma AG, PO Box, CH-4002, Basel, Switzerland, Amgen, Inc, One Amgen Center Drive, Thousand Oaks, CA 91320, Janssen Research & Development, a division
  • Jarvis P; *AstraZeneca R&D Mölndal, Pepparedsleden 1, 431 83, Mölndal, Sweden, GlaxoSmithKline, Park Road, Ware, Hertfordshire, SG12 ODP, UK, Novartis Pharma AG, PO Box, CH-4002, Basel, Switzerland, Amgen, Inc, One Amgen Center Drive, Thousand Oaks, CA 91320, Janssen Research & Development, a division
  • Ju H; *AstraZeneca R&D Mölndal, Pepparedsleden 1, 431 83, Mölndal, Sweden, GlaxoSmithKline, Park Road, Ware, Hertfordshire, SG12 ODP, UK, Novartis Pharma AG, PO Box, CH-4002, Basel, Switzerland, Amgen, Inc, One Amgen Center Drive, Thousand Oaks, CA 91320, Janssen Research & Development, a division
  • Leishman D; *AstraZeneca R&D Mölndal, Pepparedsleden 1, 431 83, Mölndal, Sweden, GlaxoSmithKline, Park Road, Ware, Hertfordshire, SG12 ODP, UK, Novartis Pharma AG, PO Box, CH-4002, Basel, Switzerland, Amgen, Inc, One Amgen Center Drive, Thousand Oaks, CA 91320, Janssen Research & Development, a division
  • Leong L; *AstraZeneca R&D Mölndal, Pepparedsleden 1, 431 83, Mölndal, Sweden, GlaxoSmithKline, Park Road, Ware, Hertfordshire, SG12 ODP, UK, Novartis Pharma AG, PO Box, CH-4002, Basel, Switzerland, Amgen, Inc, One Amgen Center Drive, Thousand Oaks, CA 91320, Janssen Research & Development, a division
  • McMahon N; *AstraZeneca R&D Mölndal, Pepparedsleden 1, 431 83, Mölndal, Sweden, GlaxoSmithKline, Park Road, Ware, Hertfordshire, SG12 ODP, UK, Novartis Pharma AG, PO Box, CH-4002, Basel, Switzerland, Amgen, Inc, One Amgen Center Drive, Thousand Oaks, CA 91320, Janssen Research & Development, a division
  • Mead A; *AstraZeneca R&D Mölndal, Pepparedsleden 1, 431 83, Mölndal, Sweden, GlaxoSmithKline, Park Road, Ware, Hertfordshire, SG12 ODP, UK, Novartis Pharma AG, PO Box, CH-4002, Basel, Switzerland, Amgen, Inc, One Amgen Center Drive, Thousand Oaks, CA 91320, Janssen Research & Development, a division
  • Milliken P; *AstraZeneca R&D Mölndal, Pepparedsleden 1, 431 83, Mölndal, Sweden, GlaxoSmithKline, Park Road, Ware, Hertfordshire, SG12 ODP, UK, Novartis Pharma AG, PO Box, CH-4002, Basel, Switzerland, Amgen, Inc, One Amgen Center Drive, Thousand Oaks, CA 91320, Janssen Research & Development, a division
  • Suter W; *AstraZeneca R&D Mölndal, Pepparedsleden 1, 431 83, Mölndal, Sweden, GlaxoSmithKline, Park Road, Ware, Hertfordshire, SG12 ODP, UK, Novartis Pharma AG, PO Box, CH-4002, Basel, Switzerland, Amgen, Inc, One Amgen Center Drive, Thousand Oaks, CA 91320, Janssen Research & Development, a division
  • Teisman A; *AstraZeneca R&D Mölndal, Pepparedsleden 1, 431 83, Mölndal, Sweden, GlaxoSmithKline, Park Road, Ware, Hertfordshire, SG12 ODP, UK, Novartis Pharma AG, PO Box, CH-4002, Basel, Switzerland, Amgen, Inc, One Amgen Center Drive, Thousand Oaks, CA 91320, Janssen Research & Development, a division
  • Van Ammel K; *AstraZeneca R&D Mölndal, Pepparedsleden 1, 431 83, Mölndal, Sweden, GlaxoSmithKline, Park Road, Ware, Hertfordshire, SG12 ODP, UK, Novartis Pharma AG, PO Box, CH-4002, Basel, Switzerland, Amgen, Inc, One Amgen Center Drive, Thousand Oaks, CA 91320, Janssen Research & Development, a division
  • Vargas HM; *AstraZeneca R&D Mölndal, Pepparedsleden 1, 431 83, Mölndal, Sweden, GlaxoSmithKline, Park Road, Ware, Hertfordshire, SG12 ODP, UK, Novartis Pharma AG, PO Box, CH-4002, Basel, Switzerland, Amgen, Inc, One Amgen Center Drive, Thousand Oaks, CA 91320, Janssen Research & Development, a division
  • Wallis R; *AstraZeneca R&D Mölndal, Pepparedsleden 1, 431 83, Mölndal, Sweden, GlaxoSmithKline, Park Road, Ware, Hertfordshire, SG12 ODP, UK, Novartis Pharma AG, PO Box, CH-4002, Basel, Switzerland, Amgen, Inc, One Amgen Center Drive, Thousand Oaks, CA 91320, Janssen Research & Development, a division
  • Valentin JP; *AstraZeneca R&D Mölndal, Pepparedsleden 1, 431 83, Mölndal, Sweden, GlaxoSmithKline, Park Road, Ware, Hertfordshire, SG12 ODP, UK, Novartis Pharma AG, PO Box, CH-4002, Basel, Switzerland, Amgen, Inc, One Amgen Center Drive, Thousand Oaks, CA 91320, Janssen Research & Development, a division
Toxicol Sci ; 142(2): 427-35, 2014 Dec.
Article in En | MEDLINE | ID: mdl-25246669
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Clinical Trials, Phase I as Topic / Drug Industry / Drug Evaluation, Preclinical / Drug-Related Side Effects and Adverse Reactions / Translational Research, Biomedical Type of study: Diagnostic_studies / Prognostic_studies Limits: Animals / Humans Language: En Journal: Toxicol Sci Journal subject: TOXICOLOGIA Year: 2014 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Clinical Trials, Phase I as Topic / Drug Industry / Drug Evaluation, Preclinical / Drug-Related Side Effects and Adverse Reactions / Translational Research, Biomedical Type of study: Diagnostic_studies / Prognostic_studies Limits: Animals / Humans Language: En Journal: Toxicol Sci Journal subject: TOXICOLOGIA Year: 2014 Type: Article